Hensify (crystalline hafnium oxide) / Nanobiotix, J&J 
Welcome,         Profile    Billing    Logout  
 1 Disease   11 Trials   11 Trials   368 News 


12345»
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J, epinephrine / Generic mfg.
    Review, Journal, IO biomarker:  Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives. (Pubmed Central) -  May 19, 2024   
    As of today, IT therapies lack sufficient evidence to recommend their use in clinical practice. Continuing research on potential molecules, patient selection, safe administration of injections and controlled randomized trials are needed to assess their added benefit.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
    Early signs of efficacy in patients with anti-PD-1 na (Hall A; Poster Bd #: 338) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_3486;    
    P1
    NBTXR3/RT/anti-PD-1 combination was feasible and well tolerated. Early data suggest the addition of NBTXR3/RT to ICI showed evidence of efficacy, including in patients who failed prior ICI, opening up an opportunity to further explore the ability of NBTXR3/RT to mitigate primary or secondary resistance to ICI.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Analysis of cancer cells response to radiotherapy activated NBTXR3 nanoparticles (Section 12) -  Mar 5, 2024 - Abstract #AACR2024AACR_5939;    
    Upon activation by RT, NBTXR3 within lysosomes induces lysosomal membrane permeabilization (LMP), resulting in an increase in lipid peroxidation, inducing regulation of fatty acid oxidation genes, and impacting mitochondrial genes expression, such as respirasome. These findings provide a deeper insight into the early biological effects of NBTXR3+RT in comparison to RT alone.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Analysis of NBTXR3 nanoparticles recapture after release by dying cells (Section 15) -  Mar 5, 2024 - Abstract #AACR2024AACR_5639;    
    Furthermore, we demonstrate in vitro that nanoparticles taken up by these tumor cells and subsequently released upon their death can be reinternalized by other tumor cells, thus facilitating their destruction by RT. These initial findings provide a deeper insight into the behavior of NBTXR3.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J, EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
    Journal:  Nanotheranostics: A Cutting-Edge Technology for Cancer Management. (Pubmed Central) -  Mar 5, 2024   
    These initial findings provide a deeper insight into the behavior of NBTXR3. The present review summarizes different nanotheranostic platforms and nanotheranostic candidates in clinical trials (AGuIX
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Review, Journal:  Synthesis and Bioapplication of Emerging Nanomaterials of Hafnium. (Pubmed Central) -  Jan 17, 2024   
    The promising clinical results of NBTXR3, a high-Z radiosensitizing nanomaterial derived from hafnium, have demonstrated translational potential of this metal...A discussion and future perspective section highlights clinical progress and elaborates on current challenges. By focusing on factors impacting applicational effectiveness and examining limitations this review aims to support researchers and expedite clinical translation of future hafnium-based nanomedicine.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Journal, PD(L)-1 Biomarker, IO biomarker:  Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization. (Pubmed Central) -  Jan 8, 2024   
    The subsequent significant increase in lipid peroxidation partially explains the enhanced cancer cell killing capacity of NBTXR3?+?RT compared to RT, potentially by promoting ferroptosis. This study improves our understanding of the cellular mechanisms underlying NBTXR3?+?RT and highlights its potential as an agnostic therapeutic strategy for solid cancers treatment.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Induction of lysosomal membrane permeabilization by radiotherapy-activated NBTXR3 nanoparticles (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1397;    
    P2/3
    The results presented here suggest that the lysosomal membrane permeabilization (LMP) induced by NBTXR3+RT may promote lipid peroxidation and, consequently, ferroptosis. These findings highlight the distinctive nature of the biological responses triggered by NBTXR3+RT and could potentially explain, at least in part, the immunomodulatory capabilities of these nanoparticles.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Enhancing DNA damage and micronuclei production in human cancer cell lines through radiotherapy-activated NBTXR3 nanoparticles (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1395;    
    Our in vitro findings demonstrate that a single dose of 4Gy with NBTXR3+RT can promote DSBs and MN generation in tested cell lines. These results suggest that the immunomodulatory properties previously observed in vivo with NBTXR3+RT could be linked to increased DNA damage, particularly MN production, which is known to play a crucial role in activating the cGAS-STING pathway, promoting IFN-b secretion, a pivotal factor in immune response priming.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Review, Journal:  Recent Advances in Metal-Based NanoEnhancers for Particle Therapy. (Pubmed Central) -  Mar 30, 2023   
    Furthermore, the future challenges and development of NREs for PT are presented for clinical translation. Finally, we propose a roadmap to pursue future studies to strengthen the interplay of particle therapy and nanomedicine.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Early biological impacts of radiotherapy-activated NBTXR3 nanoparticles (Section 3; Poster Board #14) -  Mar 14, 2023 - Abstract #AACR2023AACR_5393;    
    P2/3
    Following LMP, we measured a significant increase of in lipid peroxidation. These first elements allow a better understanding of the early biological consequences induced by NBTXR3+RT, compared to RT alone.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  NBTXR3-102: NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx (clinicaltrials.gov) -  Dec 29, 2022   
    P1,  N=75, Active, not recruiting, 
    These first elements allow a better understanding of the early biological consequences induced by NBTXR3+RT, compared to RT alone. Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Feb 2023
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J, Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Combination therapy:  Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) -  Dec 5, 2022   
    P2,  N=0, Withdrawn, 
    Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Feb 2023 N=80 --> 0 | Trial completion date: May 2025 --> Nov 2022 | Active, not recruiting --> Withdrawn | Trial primary completion date: May 2025 --> Nov 2022
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Preclinical, Journal:  NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. (Pubmed Central) -  Nov 22, 2022   
    Remarkably, previously treated with NBTXR3-containing treatment, the survivor mice exhibited a long-lasting antitumor memory immune response. This data provides compelling evidence of the efficacy of NBTXR3 to synergize with the immunoradiotherapy approach when combined with an anti-PD1 and multiple checkpoints such as a second generation anti-CTLA4 and show the potential for clinical uses of antitumor immunomodulatory effects of NBTXR3.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Review, Journal:  The emerging role of cancer nanotechnology in the panorama of sarcoma. (Pubmed Central) -  Nov 4, 2022   
    Recently, a new nanosystem formulation NBTXR3 for the treatment of sarcoma has landed in a phase 2-3 trial...Moreover, the sarcoma patient management exploiting nanotechnology products will be summed up. Finally, an overlook on future perspectives will be provided.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Radiotherapy-activated NBTXR3 nanoparticles induce Interferon Beta secretion by cancer cells (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_1430;    
    Our in vitro data show that NBTXR3+RT can significantly enhance the secretion of IFN-beta by these cells, with only a single dose of 4Gy. These results suggest that the immunomodulatory capacities of NBTXR3+RT measured in vivo could be explained, at least in part, by a greater secretion of IFN-beta, a cytokine known to play a central role in the priming of immune response.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Journal:  Ultrathin Hafnium Disulfide Atomic Crystals with ROS-Scavenging and Colon-Targeting Capabilities for Inflammatory Bowel Disease Treatment. (Pubmed Central) -  Oct 4, 2022   
    The exciting success of NBTXR3 in the clinic has triggered a tumult of activities in the design and development of hafnium-based nanoparticles...Encouragingly, upon oral or intravenous administration, HfS@TA quickly inhibited inflammation and repaired the intestinal mucosa barrier in both dextran sodium sulfate and 2,4,6-trinitrobenzenesulfonic acid induced IBD models. This work demonstrated that ultrathin HfS@TA atomic crystals with enhanced colon accumulation were promising for the targeted therapy of IBD.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Trial primary completion date:  NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (clinicaltrials.gov) -  Jul 26, 2022   
    P1,  N=24, Recruiting, 
    NBTXR3 demonstrated efficacy in a phase II/III study in patients with STS, and promising signs of efficacy have been observed in other tumor types. Trial primary completion date: Oct 2022 --> Oct 2023